Opioid Overdose Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

Las Vega (Nevada), United States //- "Opioid Overdose Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Opioid Overdose Therapeutics Market.

The report provides a detailed description of the Opioid Overdose drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Opioid Overdose Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/opioid-overdose-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Opioid Overdose Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Opioid Overdose therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Overdose treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Opioid Overdose drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Opioid Overdose treatment market.

Learn More about the Clinical and Commercial Development Activities in the Opioid Overdose Therapeutics Domain:
https://www.delveinsight.com/report-store/opioid-overdose-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Opioid Overdose Therapeutics Analysis
Currently, the treatment of opioid overdose is given at the scene or at emergency department care. Management at the scene involves using Endotracheal intubation. Naloxone is administered to reverse respiratory depression. Buprenorphine and activated charcoal are also utilized. The opioid overdose market is looking forward to new treatment methods which can better resolve the unmet needs in the current treatment domain.

In May 22, 2023, Indivior announced that the US FDA approved OPVEE (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long-duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death. OPVEE was designed to address the challenges of today's opioid crisis.

Moreover, Nasus Pharma is working to develop Intranasal Naloxone (FMXIN001). FMXIN001 was developed by blending drug microspheres produced by spray drying with larger lactose monohydrate particles, that serve as excipients. The powder was fully characterized to control the chemical composition and particle size distribution, and then filled into Unit dose Devices forming ready-to-use drug-device products.

Get an in-depth Assessment of the Emerging Therapies and Opioid Overdose Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/opioid-overdose-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Opioid Overdose Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Scope of the Report
• Therapeutic pipeline activity and therapeutic assessment of the products by clinical development stage, product type, route of administration, molecule type, and MOA
• Key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details
• Detailed assessment of the research and development progress and trial details
• Coverage of dormant and discontinued pipeline projects

Request for Sample PDF to Understand More About the Opioid Overdose Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/opioid-overdose-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Opioid Overdose Current Treatment Patterns
4. Opioid Overdose - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Opioid Overdose Late-Stage Products (Phase-III)
7. Opioid Overdose Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Opioid Overdose Discontinued Products
13. Opioid Overdose Product Profiles
14. Opioid Overdose Companies
15. Opioid Overdose Drugs
16. Dormant and Discontinued Products
17. Opioid Overdose Unmet Needs
18. Opioid Overdose Future Perspectives
19. Opioid Overdose Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/opioid-overdose-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.